First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch
Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man.
The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours:
Liquidia’s Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH
The FDA has granted tentative approval to Liquidia Corporation’s (NASDAQ:LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) to improve exercise…
United Therapeutics Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q3 earnings of $228.70 million, an increase from Q2 of 2.93%. Sales dropped to $444.70 million, a 0.4% decrease between quarters.
United Therapeutics Q3 Adj. EPS $4.16 Beats $3.59 Estimate, Sales $444.70M Beat $421.45M Estimate
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $4.16 per share which beat the analyst consensus estimate of $3.59 by 15.88 percent. This is a 7.22 percent increase over earnings of $3.88 per share from
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes.
PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
3D Systems, United Therapeutics Reports Expansion Of Bioprinting Program
Amendment expands program from a singular focus on the bioprinting of human lung scaffolds to the development and demonstration of two additional human organs
Amendment will become effective upon closing of 3D
United Therapeutics Details New Data Presented At CHEST Annual Meeting 2021
United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today detailed the new clinical and real-world evidence on pulmonary arterial